Glucose‐Dependent Insulinotropic Polypeptide/Glucagon‐Like‐Peptide‐1 Use Following 10‐Session Cognitive–Behavioural Therapy for Binge‐Eating Disorder: A Single‐Case Experimental Design
European Eating Disorders Review · 2026
DOI: 10.1002/erv.70135 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Eating Disorders Review, 2026. Verfasst von Ashley Dunford und 4 weiteren Autor:innen. Beteiligte Einrichtung: Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Binge-Eating Disorder, Cognitive Behavioral Therapy, Gastric Inhibitory Polypeptide. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Objective
Many patients with larger bodies present to eating disorder (ED) treatment seeking weight loss. Whether glucose‐dependent insulinotropic polypeptide/glucagon‐like‐peptide receptor agonists (GIP/GLP‐1s) are helpful or harmful for such patients remains unknown. This single case experimental design study examined the effects of Tirzepatide (7.5 mg/0.05 mL), a GIP/GLP‐1 following 10‐session cognitive‐behavioural therapy (CBT‐T) in a patient with binge‐eating disorder (BED) and obesity.
Method
A 37‐year‐old female presented to an outpatient ED clinic with BED and a body mass index of 68.9 kg/m 2 . We assessed weekly and then monthly ED behaviours and cognitions using the Eating Disorder 15 (ED‐15) across two treatment phases: CBT‐T (3 months) and GIP/GLP‐1 administration (9 months).
Results
As hypothesised, ED cognitions and binge frequency decreased during CBT‐T. Also as hypothesised, during GIP/GLP‐1 phase, binge frequency remained low and dietary restraint absent. We observed continued reductions in ED cognitions and 39‐pound weight loss.
Discussion
GIP/GLP‐1 treatment after CBT‐T was followed by ED remission and weight loss without serious adverse events. CBT‐T skills may mitigate risk of disordered eating during GIP/GLP‐1 use. The combination of psychotherapy and GIP/GLP‐1s may further reduce binge‐eating and lead to weight loss. Research is needed to explore risks and benefits of GIP/GLP‐1s for patients with EDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Mass General Brigham Multidisciplinary Eating Disorders Research Collaborative, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Ashley Dunford, Stefania Yee, Jennifer J Thomas, Kamryn T Eddy, Esther Dechant
Förderung
- NIMH NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Dunford, A., Yee, S., Thomas, J. J., Eddy, K. T., & Dechant, E. (2026). Glucose‐Dependent Insulinotropic Polypeptide/Glucagon‐Like‐Peptide‐1 Use Following 10‐Session Cognitive–Behavioural Therapy for Binge‐Eating Disorder: A Single‐Case Experimental Design. European Eating Disorders Review. https://doi.org/10.1002/erv.70135
Vancouver
Dunford A, Yee S, Thomas JJ, Eddy KT, Dechant E. Glucose‐Dependent Insulinotropic Polypeptide/Glucagon‐Like‐Peptide‐1 Use Following 10‐Session Cognitive–Behavioural Therapy for Binge‐Eating Disorder: A Single‐Case Experimental Design. European Eating Disorders Review. 2026. doi:10.1002/erv.70135
BibTeX
@article{Dunford2026,
author = {Dunford, Ashley and Yee, Stefania and Thomas, Jennifer J and Eddy, Kamryn T and Dechant, Esther},
title = {Glucose‐Dependent Insulinotropic Polypeptide/Glucagon‐Like‐Peptide‐1 Use Following 10‐Session Cognitive–Behavioural Therapy for Binge‐Eating Disorder: A Single‐Case Experimental Design},
journal = {European Eating Disorders Review},
year = {2026},
doi = {10.1002/erv.70135}
}
EUVIMED